Abstract:Background: Previous studies have demonstrated an association between hyperuricemia and cardiovascular disease (CVD). The Framingham study confirmed that patients with high atherosclerotic risks (HARs) had worse prognoses. However, after adjusting for confounding factors, the association between serum uric acid (SUA) and all-cause mortality and cardiovascular mortality remains unclear, especially for HAR patients.Objective: The aim of this study was to reveal the relationship of SUA with all-cause and cardiovascular mortality in HAR patients.Methods: This multicenter cohort study enrolled 3,047 participants, and the follow-up was 68.85 ± 11.37 months. Factors related to cardiovascular and all-cause mortality were tested by multivariate Cox regression analysis. Restricted cubic splines (RCSs) with knots were used to explore the shape of the dose–response relationship with SUA and the hazard ratio (HR) of all-cause and CVD mortality. SUA transformed by RCS was added to the Cox regression model as an independent variable, and all-cause and CVD mortality scores were calculated. Survival receiver operating characteristic curves were produced using a regression model predicting the score.Results: SUA demonstrated a “U-shaped” relationship with all-cause and cardiovascular mortality. SUA predicted all-cause and CVD mortality, with cutoff values of values of >370.5 μmol/L for males and >327.65 μmol/L for females and <180.5 μmol/L for males and <165.7 μmol/L for females, respectively. The survival ROC curve indicated that SUA is able to predict all-cause and CVD mortality, with areas under the curve of 0.702 and 0.711, respectively. The HRs of all-cause mortality (male and female) with hyperuricemia and hypouricemia were 2.08 and 2.01 and 2.04 and 1.98, respectively, and the HRs of CVD mortality (male and female) were 2.09 and 1.79, and 2.02 and 1.89, respectively.Conclusion: Abnormal SUA levels were significant and independent risk factors for all-cause and CVD mortality. Hyperuricemia and hypouricemia increased mortality in both males and females. Routine SUA evaluation and intensive management are needed for HAR patients.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT03616769.

Serum Uric Acid Levels Predict Mortality Risk in Male Amyotrophic Lateral Sclerosis Patients

Serum Uric Acid Levels in Patients with Amyotrophic Lateral Sclerosis: a Meta-Analysis.

Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population

[Association of Serum Uric Acid Level with Amyotrophic Lateral Sclerosis].

Association Between Serum Uric Acid Levels and Long-Term Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease: a Nationwide Cohort Study

Associations of Serum Uric Acid Levels with Liver Disease-Related Morbidity and Mortality: A Prospective Cohort Study of the UK Biobank.

High serum uric acid level is a mortality risk factor in peritoneal dialysis patients: a retrospective cohort study

Serum Creatinine Levels in Patients with Amyotrophic Lateral Sclerosis: a Systematic Review and Meta-Analysis

Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis

An Exploratory Study of Serum Creatinine Levels in Patients with Amyotrophic Lateral Sclerosis

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone

Cystatin C is associated with poor survival in amyotrophic lateral sclerosis patients

High serum uric acid levels are protective against cognitive impairment in amyotrophic lateral sclerosis

The serum lipid profiles of amyotrophic lateral sclerosis patients: A study from south-west China and a meta-analysis.

Serum uric acid as a predictor of mortality in patients with stroke: results from National Health and Nutrition Examination Survey 2007–2016

Serum Uric Acid Revealed a U-Shaped Relationship with All-Cause Mortality and Cardiovascular Mortality in High Atherosclerosis Risk Patients: the ASSURE Study.

Serum uric acid and mortality in metabolic dysfunction-associated steatotic liver disease: subgroup differences

Associations of cerebrospinal fluid profiles with severity and mortality risk of amyotrophic lateral sclerosis

Association Between Serum Uric Acid Level and Multiple System Atrophy: A Meta-Analysis

Elevated serum ferritin level as a predictor of reduced survival in patients with sporadic amyotrophic lateral sclerosis in China: a retrospective study

Plasma Uric Acid Helps Predict Cognitive Impairment in Patients with Amyotrophic Lateral Sclerosis